172 related articles for article (PubMed ID: 37579206)
21. B cell immunodominance in primary hepatitis C virus infection.
Brasher NA; Eltahla AA; Underwood A; Boo I; Rizzetto S; Walker MR; Rodrigo C; Luciani F; Maher L; Drummer HE; Tedla N; Lloyd AR; Bull RA
J Hepatol; 2020 Apr; 72(4):670-679. PubMed ID: 31785346
[TBL] [Abstract][Full Text] [Related]
22. Studies of hepatitis C virus in chimpanzees and their importance for vaccine development.
Bukh J; Forns X; Emerson SU; Purcell RH
Intervirology; 2001; 44(2-3):132-42. PubMed ID: 11509874
[TBL] [Abstract][Full Text] [Related]
23. Molecular and immunological significance of chimpanzee major histocompatibility complex haplotypes for hepatitis C virus immune response and vaccination studies.
Mizukoshi E; Nascimbeni M; Blaustein JB; Mihalik K; Rice CM; Liang TJ; Feinstone SM; Rehermann B
J Virol; 2002 Jun; 76(12):6093-103. PubMed ID: 12021342
[TBL] [Abstract][Full Text] [Related]
24. Immune responses to hepatitis C virus (HCV) infection and the prospects for an effective HCV vaccine or immunotherapies.
Lauer GM
J Infect Dis; 2013 Mar; 207 Suppl 1():S7-S12. PubMed ID: 23390305
[TBL] [Abstract][Full Text] [Related]
25. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus.
Torresi J; Johnson D; Wedemeyer H
J Hepatol; 2011 Jun; 54(6):1273-85. PubMed ID: 21236312
[TBL] [Abstract][Full Text] [Related]
26. Genetic vaccination with Flt3-L and GM-CSF as adjuvants: Enhancement of cellular and humoral immune responses that results in protective immunity in a murine model of hepatitis C virus infection.
Encke J; Bernardin J; Geib J; Barbakadze G; Bujdoso R; Stremmel W
World J Gastroenterol; 2006 Nov; 12(44):7118-25. PubMed ID: 17131473
[TBL] [Abstract][Full Text] [Related]
27. Transmitted/Founder Viruses Rapidly Escape from CD8+ T Cell Responses in Acute Hepatitis C Virus Infection.
Bull RA; Leung P; Gaudieri S; Deshpande P; Cameron B; Walker M; Chopra A; Lloyd AR; Luciani F
J Virol; 2015 May; 89(10):5478-90. PubMed ID: 25740982
[TBL] [Abstract][Full Text] [Related]
28. Recombinant adenoviral vector expressing HCV NS4 induces protective immune responses in a mouse model of Vaccinia-HCV virus infection: a dose and route conundrum.
Singh S; Vedi S; Li W; Samrat SK; Kumar R; Agrawal B
Vaccine; 2014 May; 32(23):2712-21. PubMed ID: 24631092
[TBL] [Abstract][Full Text] [Related]
29. Immune responses against hepatitis C virus genotype 3a virus-like particles in mice: A novel VLP prime-adenovirus boost strategy.
Kumar A; Das S; Mullick R; Lahiri P; Tatineni R; Goswami D; Bhat P; Torresi J; Gowans EJ; Karande AA; Das S
Vaccine; 2016 Feb; 34(8):1115-25. PubMed ID: 26700891
[TBL] [Abstract][Full Text] [Related]
30. Vaccination with protein-transduced dendritic cells elicits a sustained response to hepatitis C viral antigens.
Kuzushita N; Gregory SH; Monti NA; Carlson R; Gehring S; Wands JR
Gastroenterology; 2006 Feb; 130(2):453-64. PubMed ID: 16472599
[TBL] [Abstract][Full Text] [Related]
31. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV.
Forns X; Payette PJ; Ma X; Satterfield W; Eder G; Mushahwar IK; Govindarajan S; Davis HL; Emerson SU; Purcell RH; Bukh J
Hepatology; 2000 Sep; 32(3):618-25. PubMed ID: 10960458
[TBL] [Abstract][Full Text] [Related]
32. Methods to Evaluate Novel Hepatitis C Virus Vaccines.
Ahlén G; Frelin L
Methods Mol Biol; 2016; 1403():221-44. PubMed ID: 27076133
[TBL] [Abstract][Full Text] [Related]
33. Induction of Genotype Cross-Reactive, Hepatitis C Virus-Specific, Cell-Mediated Immunity in DNA-Vaccinated Mice.
Wijesundara DK; Gummow J; Li Y; Yu W; Quah BJ; Ranasinghe C; Torresi J; Gowans EJ; Grubor-Bauk B
J Virol; 2018 Apr; 92(8):. PubMed ID: 29437963
[TBL] [Abstract][Full Text] [Related]
34. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory.
Swadling L; Capone S; Antrobus RD; Brown A; Richardson R; Newell EW; Halliday J; Kelly C; Bowen D; Fergusson J; Kurioka A; Ammendola V; Del Sorbo M; Grazioli F; Esposito ML; Siani L; Traboni C; Hill A; Colloca S; Davis M; Nicosia A; Cortese R; Folgori A; Klenerman P; Barnes E
Sci Transl Med; 2014 Nov; 6(261):261ra153. PubMed ID: 25378645
[TBL] [Abstract][Full Text] [Related]
35. Challenge Inoculum for Hepatitis C Virus Controlled Human Infection Model.
Liang TJ; Law JLM; Pietschmann T; Ray SC; Bukh J; Bull R; Chung RT; Tyrrell DL; Houghton M; Rice CM
Clin Infect Dis; 2023 Aug; 77(Suppl 3):S257-S261. PubMed ID: 37579208
[TBL] [Abstract][Full Text] [Related]
36. Protective vaccination with hepatitis C virus NS3 but not core antigen in a novel mouse challenge model.
El-Gogo S; Staib C; Lasarte JJ; Sutter G; Adler H
J Gene Med; 2008 Feb; 10(2):177-86. PubMed ID: 18076128
[TBL] [Abstract][Full Text] [Related]
37. Adenovirus-vectored T cell vaccine for hepacivirus shows reduced effectiveness against a CD8 T cell escape variant in rats.
Hartlage AS; Dravid P; Walker CM; Kapoor A
PLoS Pathog; 2021 Mar; 17(3):e1009391. PubMed ID: 33735321
[TBL] [Abstract][Full Text] [Related]
38. Vaccination to prevent T cell subversion can protect against persistent hepacivirus infection.
Hartlage AS; Murthy S; Kumar A; Trivedi S; Dravid P; Sharma H; Walker CM; Kapoor A
Nat Commun; 2019 Mar; 10(1):1113. PubMed ID: 30846697
[TBL] [Abstract][Full Text] [Related]
39. Development of a heterologous, multigenotype vaccine against hepatitis C virus infection.
Encke J; Radunz W; Eisenbach C; Geib J; Gehrke S; Pfaff E; Stremmel W
Eur J Clin Invest; 2007 May; 37(5):396-406. PubMed ID: 17461986
[TBL] [Abstract][Full Text] [Related]
40. Anti-hepatitis C virus T-cell immunity in the context of multiple exposures to the virus.
Pfafferott K; Deshpande P; McKinnon E; Merani S; Lucas A; Heckerman D; Mallal S; John M; Gaudieri S; Lucas M
PLoS One; 2015; 10(6):e0130420. PubMed ID: 26107956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
